WISDOM Project: A New Era in Predictive and Personalised Medicine
WISDOM project, a groundbreaking initiative funded by the European Commission, officially kicked-off on June 4-5, 2024. This five-year endeavour aims to mitigate the impact of chronic immune-mediated diseases (CIMDs) that affect 10% of Europeans by integrating healthcare and research data.
Harnessing AI for Early Detection and Personalised Treatment
By leveraging artificial intelligence, WISDOM seeks to transform complex biological information from existing data sources into clinically applicable models. Project coordinator Ingrid Skelton Kockum emphasized,
"Using AI, we will transform complex biological information from existing data sources into clinically applicable models. If we can identify and treat patients with chronic inflammatory diseases at an earlier stage, there is a good chance of slowing the progression of the disease and reducing symptoms and relapses. An improved prediction of disease severity would also allow for better use of current treatments to avoid both over and under treatment."
Ensuring Patient-Centric Research
The European Multiple Sclerosis Platform (EMSP), a key partner in WISDOM, is dedicated to placing patients' voices at the forefront of research efforts. Elisabeth Kasilingam, CEO of EMSP, stated,
"As a key partner in the WISDOM project, the European Multiple Slerosis Platform (EMSP) is committed to ensuring that patients' voices and perspectives are central to our research efforts. By actively engaging with patient communities, EMSP aims to contribute to the development of personalsed healthcare solutions that truly address the needs of those living with MS and other chronic immune-mediated diseases."
Secure and Compliant Data Sharing
A significant challenge for WISDOM is the efficient reuse of existing clinical registry and research data while ensuring privacy and compliance with regulations like GDPR and the upcoming EHDS legislation. Timo Miettinen, Chief Technology Officer at VEIL.AI, highlighted,
"A key challenge of the WISDOM project is the efficient re-use of the existing clinical registry and research data. With the EHDS legislation coming up, ensuring the privacy and safety of sensitive health data while enabling its sharing and analysis is a major concern. This is where VEIL.AI’s next generation anonymisation technology plays a critical role. The integration of VEIL.AI's anonymisation solutions ensures that sensitive health data can be utilised effectively while remaining compliant with privacy regulations like GDPR and EHDS. Our ultimate objective is to enhance the treatment and monitoring of CIMDs across Europe."
Looking Ahead
WISDOM aims to develop and validate tools for risk stratification, disease outcome prediction, and personalised interventions. These efforts are expected to expedite the identification and follow-up of individuals at high risk of developing CIMDs, leading to more accurate treatments and lifestyle recommendations.
For more detailed information, you can read the full press release here.
